Diatranz Otsuka

Name

Diatranz Otsuka

Legal name

Diatranz Otsuka Limited

Website

https://dolglobal.com

Company type

Private

Founded year

2011

Operating status

Operating

Ownership category

akta.pro rank

Product category

Molecular Diagnostic and Analytical Services

NAICS

Medical Laboratories (621511), Pharmaceutical Preparation Manufacturing (325412), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Services-Medical Laboratories (8071), Pharmaceutical Preparations (2834)

akta.pro primary industry

Type 1 Diabetes Care (HLAKADAB)

akta.pro secondary industries

Sample Logistics, Biorepository & IVD Kit Management (Trial Support) (HLAGAEAI), Diabetes (General) (HLAKADAA)

Keywords

• Molecular diagnostic services
• Pharmaceutical analytical testing
• Cell therapy products
• Biosafety testing services
• Xenotransplantation services

Headquarters

HQ city

Auckland

HQ country

New Zealand

HQ region

Oceania

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Others

Revenue model

1. DIABECELL Development and Commercialisation: DOL retains rights to commercialise DIABECELL in the rest of the world (outside Japan and USA, which are licensed to OPF). DIABECELL is a cell therapy product for Type 1 diabetes using encapsulated pig islets.
2. Quality Assurance Testing Services to OPF: DOL provides quality assurance testing services to its parent company Otsuka Pharmaceutical Factory, including verification of herd safety and diagnostic testing of human clinical samples for Phase III clinical trials in the USA.
3. Molecular Diagnostic and Analytical Services: DOL provides advanced molecular diagnostic and analytical services to pharmaceutical, medical device and xenotransplantation customers across the globe, supporting their manufacturing processes and clinical development.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Diatranz Otsuka Limited provides advanced molecular diagnostic and analytical services to pharmaceutical, medical device, and xenotransplantation customers globally, including sterility/endotoxin/mycoplasma QC testing, viral and biosafety testing, DPF herd monitoring, PERV screening, and clinical bioassays. The company also develops and holds rights to DIABECELL, an encapsulated pig islet cell therapy intended to restore natural blood glucose control in people with Type 1 diabetes.

Product overview

Diatranz Otsuka Limited operates as a specialized molecular diagnostic and analytical services company with a core proprietary therapy. Their main product is DIABECELL, a cell therapy using encapsulated pig islets for Type 1 diabetes treatment. Complementing this, they offer a comprehensive suite of molecular diagnostic and analytical testing services: Rapid Microbial QC (sterility, endotoxin, mycoplasma), Viral/Biosafety testing, Xenotransplantation services (DPF herd monitoring, PERV screening), and Clinical Bioassays (biomarker analysis, genotyping, cytokine profiling). The services are engineered to meet international manufacturing and clinical monitoring regulations for pharmaceutical, medical device, and xenotransplantation customers.

Differentiator

Problem solved

Functional benefit

Brands

• DIABECELL: Living islet cells treatment for Type 1 diabetes using encapsulated pig islets to restore the body's natural blood glucose control.

Products and services

• DIABECELL Living islet cells derived from encapsulated pig islets that are transplanted into patients to restore the intrinsic ability to control blood glucose for people living with Type 1 diabetes. The islets are protected from the patient's immune system by a jelly-like capsule.
• Rapid Microbial QC Services

Quantifiable outcome

• DIABECELL can significantly reduce unaware hypoglycemic events and allow patients to lower their insulin dosage without increasing HbA1c levels.
• +1 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Two partnerships are on record, tiered core and historical.

• Otsuka Pharmaceutical Factory, Inc. (OPF)coreStrategic or Co-development Partner · 1 January 2018In January 2018, DOL became a wholly owned subsidiary of Otsuka Pharmaceutical Factory, Inc. (OPF), one of the main operating companies of the Otsuka Group. OPF licensed rights to develop and commercialise DIABECELL in Japan and USA. OPF retained DOL's international expertise in analytical and molecular diagnostics to establish manufacturing capability and pig herd in the USA for OPF's Phase 3 study. DOL provides quality assurance testing services to OPF for Phase III trials.
• Living Cell TechnologieshistoricalStrategic or Co-development Partner · 1 January 2011Living Cell Technologies was the original joint-venture partner in establishing Diatranz Otsuka Limited in New Zealand in 2011, initially focusing on development and commercialisation of DIABECELL as a treatment for Type 1 diabetes. This joint-venture relationship preceded OPF's full acquisition of DOL in 2018.

Scale indicators4 records

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• Labcorp (Fortrea / Covance): Major clinical diagnostics and central laboratory operator with capabilities spanning routine and specialty testing for pharma trials. Comparable to DOL's medical-laboratory-style testing services offered to pharmaceutical and medical device customers.
• Catalent (Novo Holdings): Major CDMO with cell therapy manufacturing and analytical services including microbial and biosafety testing for advanced therapies. Comparable analytical-services overlap with DOL, though at much greater scale and breadth.
• Eurofins Scientific: A large international laboratory services group with pharmaceutical and clinical diagnostic testing offerings, including bioassays and microbiological QC. Comparable to DOL as a B2B molecular diagnostic / analytical services provider for pharma and medical device manufacturers.
• WuXi AppTec / WuXi Advanced Therapies: Large global CRO/CDMO with advanced therapies unit offering viral vector testing, biosafety, and cell-based assay services. Comparable to DOL's specialty testing for cell and gene therapy developers, including viral vector copy number and RCL/RCR testing.
• SGS Life Sciences: Global testing, inspection, and certification firm with a Life Sciences division providing bioanalytical and biosafety testing services for pharma. Comparable service-level mix (microbiology, biosafety, cell-based assays) to DOL's portfolio.
• Charles River Laboratories: A global CRO offering preclinical and clinical laboratory services, including microbial and viral safety testing for biologics and gene therapies. Highly comparable to DOL's sterility, endotoxin, mycoplasma, and viral biosafety testing services for pharma manufacturers, though far broader in scope and scale.

Emerging players

• ViaCyte (CRISPR Therapeutics partner): Stem-cell-derived islet cell therapy developer for Type 1 diabetes with stem cell-derived encapsulated products. Competes with DIABECELL in the same therapeutic category using a different cell source and encapsulation concept.
• Vertex Pharmaceuticals (VX-880/VX-264 cell therapy programs): Developing stem-cell-derived islet cell therapies for Type 1 diabetes, directly competing for the same patient population DIABECELL targets. Comparable as the most credible near-term competitive alternative in T1D cell therapy.

Direct peers

• Revivicor (United Therapeutics): Pioneer in xenotransplantation using genetically engineered pigs for organ and cell transplantation, including islet cell programs for diabetes. Most directly comparable to DOL on the xenotransplantation platform and DPF herd/xenosafety expertise underpinning DIABECELL.
• eGenesis: Clinical-stage xenotransplantation company developing porcine organs and islet cells, with extensive PERV and zoonotic biosafety testing needs. Comparable to DOL on the xenotransplantation development track and reliance on specialized xenosafety laboratories.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/diatranz-otsuka-limited

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Diatranz Otsuka